SCHEMBL1068264

SCHEMBL1068264

CC(C)C[C@@H](C(=O)O)N1CC(Oc2cccc(Cl)c2F)=CC1=O

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MRGPRX4 Q96LA9 1/20 0.36
HIF1A Q16665 1/20 0.36
GCK P35557 1/20 0.35
MAPT P10636 1/20 0.33
RIPK1 Q13546 4/20 0.33
MME P08473 1/20 0.33
NR1H4 Q96RI1 2/20 0.32
P2RX7 Q99572 1/20 0.32
LMNA P02545 1/20 0.32
THRB P10828 1/20 0.32
MCL1 Q07820 1/20 0.32
SLC6A2 P23975 1/20 0.32
SLC6A4 P31645 1/20 0.32
SLC6A3 Q01959 1/20 0.32
ALDH1A1 P00352 1/20 0.32
CYP1A2 P05177 1/20 0.32
CYP3A4 P08684 1/20 0.32
CYP2C9 P11712 1/20 0.32
CYP2C19 P33261 1/20 0.32
HTT P42858 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1068266 1.00 MRGPRX4 (0.36) MRGPRX4HIF1AGCKMAPTRIPK1
SCHEMBL1064249 0.90 NPC1 (0.35) HIF1AGCKMAPTRIPK1LMNA
SCHEMBL1064245 0.90 NPC1 (0.35) HIF1AGCKMAPTRIPK1LMNA
SCHEMBL1064282 0.90 CARM1 (0.36) MRGPRX4HIF1AMAPTP2RX7MCL1
SCHEMBL1066409 0.90 CARM1 (0.36) MRGPRX4HIF1AMAPTP2RX7MCL1
SCHEMBL1067362 0.89 CXCL8 (0.40) MAPTMMETHRBMCL1ALDH1A1
SCHEMBL1066976 0.89 CXCL8 (0.40) MAPTMMETHRBMCL1ALDH1A1
SCHEMBL2659036 0.89 CXCL8 (0.40) MAPTMMETHRBMCL1ALDH1A1
SCHEMBL1063687 0.89 MME (0.33) MMELMNATHRBMCL1ALDH1A1
SCHEMBL1063691 0.89 MME (0.33) MMELMNATHRBMCL1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP claimed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US claimed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US claimed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO claimed
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 MRGPRX4 3935/4885HIF1A 1409/4885GCK 2/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.